

SURGICAL ONCOLOGY
PAPER-III

Time: 3 hours

SURG ONCO/J/20/47/III

Max. Marks:100

Important Instructions:

- Attempt all questions in order.
- Each question carries 10 marks.
- Read the question carefully and answer to the point neatly and legibly.
- Do not leave any blank pages between two answers.
- Indicate the question number correctly for the answer in the margin space.
- Answer all the parts of a single question together.
- Start the answer to a question on a fresh page or leave adequate space between two answers.
- Draw table/diagrams/flowcharts wherever appropriate.

Write short notes on:

1. Mention the Gene Expression Assays available for management of Early Breast Cancer. Critically assess their clinical utility, with evidence. 3+7
2. Outline impact of trials in cutaneous melanoma with respect to: 3+3+4
 - a) Margins.
 - b) Sentinel node biopsy.
 - c) Adjuvant immunotherapy.
3. Define precision oncology. Enumerate different precision oncology trial designs with examples. 2+8
4.
 - a) Phase II Randomized Control Trials. 5+5
 - b) Discuss about a non-inferiority trial, based on one landmark. trial which was designed as a non-inferiority trial.
5.
 - a) Discuss the role of neoadjuvant therapy in bladder cancer 5+5
 - b) Discuss the various urinary diversion methods after a radical cystectomy
6. Outline organ-preservation approaches in laryngeal carcinoma. Mention the important evidences to support organ preservation in laryngeal carcinoma. 6+4
7. What is ALPPS procedure? Outline the advantages, disadvantages and evidences pertaining to the procedure. 2+3+3+2
8.
 - a) Role of neck dissection in a clinically N0 neck in oral cancers. 5+5
 - b) Sentinel lymph node biopsy in head and neck cancers.
9. Outline the risk-based approaches to organ-confined prostate cancer with evidence. 10
10.
 - a) Nephrometry score. 5+5
 - b) Evidence for Radical nephrectomy versus partial nephrectomy.
